113 related articles for article (PubMed ID: 17728795)
1. Retroviral gene transfer of tissue-type plasminogen activator targets thrombolysis in vitro and in vivo.
Gong YS; Zhang KL; Jiang XG; Wang ZW; Sun ZQ; Cai J
Gene Ther; 2007 Nov; 14(21):1537-42. PubMed ID: 17728795
[TBL] [Abstract][Full Text] [Related]
2. Tissue-type plasminogen activator gene targets thrombolysis in atriums.
Gong Y; Wang F; Li X; Gao Z; Zhang K; Fan C; Liu X
J Thromb Thrombolysis; 2010 Nov; 30(4):507-14. PubMed ID: 20924774
[TBL] [Abstract][Full Text] [Related]
3. Retrovirus-Mediated Transfection of the Tissue-type Plasminogen Activator Gene Results in Increased Thrombolysis of Blood Clots.
Wu X; Gong Y; Ding X; Cheng G; Yan W; She X; Wang C; Li X
Biochem Genet; 2019 Apr; 57(2):234-247. PubMed ID: 30218285
[TBL] [Abstract][Full Text] [Related]
4. Reduction of early vein graft thrombosis by tissue plasminogen activator gene transfer.
Thomas AC; Wyatt MJ; Newby AC
Thromb Haemost; 2009 Jul; 102(1):145-52. PubMed ID: 19572079
[TBL] [Abstract][Full Text] [Related]
5. Tissue plasminogen activator production by monocytes in venous thrombolysis.
Soo KS; Northeast AD; Happerfield LC; Burnand KG; Bobrow LG
J Pathol; 1996 Feb; 178(2):190-4. PubMed ID: 8683388
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of intravascular thrombosis and vascular smooth muscle cell proliferation by gene therapy.
Flugelman MY
Thromb Haemost; 1995 Jul; 74(1):406-10. PubMed ID: 8578496
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect on the establishment of hepatic metastasis by transduction of the tissue plasminogen activator gene to murine colon cancer.
Hayashi S; Yokoyama I; Namii Y; Emi N; Uchida K; Takagi H
Cancer Gene Ther; 1999; 6(4):380-4. PubMed ID: 10419057
[TBL] [Abstract][Full Text] [Related]
8. Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model.
Solly F; Fish R; Simard B; Bolle N; Kruithof E; Polack B; Pernod G
Cancer Gene Ther; 2008 Oct; 15(10):685-92. PubMed ID: 18535615
[TBL] [Abstract][Full Text] [Related]
9. [Preparation and characterization of recombinant retroviral vector containing t-PA cDNA].
Cui N; Peng L; Song H; Han Q; Chen H
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Mar; 11(1):50-2. PubMed ID: 15619905
[TBL] [Abstract][Full Text] [Related]
10. Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis.
Hoefer IE; Stroes ES; Pasterkamp G; Levi MM; Reekers JA; Verhagen HJ; Meijers JC; Humphries JE; Rotmans JI
J Vasc Interv Radiol; 2009 Jul; 20(7):951-8. PubMed ID: 19481472
[TBL] [Abstract][Full Text] [Related]
11. Retroviral vector-mediated expression of hirudin by human vascular endothelial cells: implications for the design of retroviral vectors expressing biologically active proteins.
Rade JJ; Cheung M; Miyamoto S; Dichek DA
Gene Ther; 1999 Mar; 6(3):385-92. PubMed ID: 10435088
[TBL] [Abstract][Full Text] [Related]
12. Construction and biological activities of human tPA eukaryotic expression plasmid.
Wu ZJ; Yang SF; Zheng SS; Shi D; Wu WW; Li DW
Hepatobiliary Pancreat Dis Int; 2004 Nov; 3(4):511-5. PubMed ID: 15567735
[TBL] [Abstract][Full Text] [Related]
13. Experimental study on establishing eukaryotic expression vector pcDNA3.1(+) TPA and its expressing activity in human skin fibroblists.
Deng HB; Yang Y; Yang JF; Tang T; Zhou WW; Liu J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 30(4):373-8. PubMed ID: 16190377
[TBL] [Abstract][Full Text] [Related]
14. Study on construction of nano tPA plasmid to prevent thrombosis after mechanical valve replacement in dogs.
Ji S; Jun J; Xiaohan Y; Xia H; Xiaolei W; Xiaoqing Y; Jianzhou G; Wenping L; Yanhui Z
J Surg Res; 2011 Jun; 168(1):e1-5. PubMed ID: 20605599
[TBL] [Abstract][Full Text] [Related]
15. Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device.
Delgado R; Frazier OH; Myers TJ; Gregoric ID; Robertson K; Shah NA; Kar B
J Heart Lung Transplant; 2005 Feb; 24(2):231-3. PubMed ID: 15701444
[TBL] [Abstract][Full Text] [Related]
16. Augmented experimental pulse-spray thrombolysis with tissue plasminogen activator, enabling dose reduction by one or more orders of magnitude.
Bookstein JJ; Bookstein FL
J Vasc Interv Radiol; 2000 Mar; 11(3):299-303. PubMed ID: 10735423
[TBL] [Abstract][Full Text] [Related]
17. Effects of intrathrombic administration of prostaglandin E1 during pulse-spray thrombolysis with tissue-type plasminogen activator in experimental thrombosis.
Valji K; Bookstein JJ
Radiology; 1993 Mar; 186(3):873-6. PubMed ID: 8430201
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen-enriched pulse-spray thrombolysis with tPA: further developments.
Bookstein JJ; Bookstein FL
J Vasc Interv Radiol; 2000; 11(10):1353-62. PubMed ID: 11099249
[TBL] [Abstract][Full Text] [Related]
19. Seeding of vascular grafts with genetically modified endothelial cells. Secretion of recombinant TPA results in decreased seeded cell retention in vitro and in vivo.
Dunn PF; Newman KD; Jones M; Yamada I; Shayani V; Virmani R; Dichek DA
Circulation; 1996 Apr; 93(7):1439-46. PubMed ID: 8641034
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions.
Lobov S; Croucher DR; Saunders DN; Ranson M
Thromb Haemost; 2008 Aug; 100(2):319-29. PubMed ID: 18690354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
